Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T Dicker

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Cancer Biology & Therapy|July 5, 2011
Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancerJean-Nicolas Gallant, Joshua E Allen, Charles D Smith, et al.
Molecular Cancer Therapeutics|December 10, 2009
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cellsJay F Dorsey, Akiva Mintz, Xiaobing Tian, et al.
Cell Cycle (Georgetown, Tex.)|August 17, 2012
Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activationHairong Cheng, Bo Hong, Lanlan Zhou, et al.
Oncotarget|January 15, 2015
The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activityJessica Wagner, Christina Leah Kline, Richard S Pottorf, et al.
Oncotarget|December 17, 2013
Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCsJoshua E Allen, Bikramajit Singh Saroya, Miriam Kunkel, et al.
The Journal of Biological Chemistry|November 24, 2006
CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradationWensheng Yang, Laura M Rozan, E Robert McDonald, et al.
Oncotarget|November 4, 2020
TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptoticMarie D Ralff, Aakash Jhaveri, Jocelyn E Ray, et al.
Molecular Cancer Therapeutics|April 21, 2017
ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent MechanismsMarie D Ralff, Christina L B Kline, Ozan C Küçükkase, et al.
Neoplasia (New York, N.Y.)|December 8, 2017
Role of Dopamine Receptors in the Anticancer Activity of ONC201Christina Leah B Kline, Marie D Ralff, Amriti R Lulla, et al.
Molecular Cancer Therapeutics|July 18, 2012
Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexesJoshua E Allen, Roger Ferrini, David T Dicker, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Cancer Biology & Therapy|July 5, 2011
Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancerJean-Nicolas Gallant, Joshua E Allen, Charles D Smith, et al.
Molecular Cancer Therapeutics|December 10, 2009
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cellsJay F Dorsey, Akiva Mintz, Xiaobing Tian, et al.
Cell Cycle (Georgetown, Tex.)|August 17, 2012
Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activationHairong Cheng, Bo Hong, Lanlan Zhou, et al.
Oncotarget|January 15, 2015
The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activityJessica Wagner, Christina Leah Kline, Richard S Pottorf, et al.
Oncotarget|December 17, 2013
Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCsJoshua E Allen, Bikramajit Singh Saroya, Miriam Kunkel, et al.
The Journal of Biological Chemistry|November 24, 2006
CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradationWensheng Yang, Laura M Rozan, E Robert McDonald, et al.
Oncotarget|November 4, 2020
TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptoticMarie D Ralff, Aakash Jhaveri, Jocelyn E Ray, et al.
Molecular Cancer Therapeutics|April 21, 2017
ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent MechanismsMarie D Ralff, Christina L B Kline, Ozan C Küçükkase, et al.
Neoplasia (New York, N.Y.)|December 8, 2017
Role of Dopamine Receptors in the Anticancer Activity of ONC201Christina Leah B Kline, Marie D Ralff, Amriti R Lulla, et al.
Molecular Cancer Therapeutics|July 18, 2012
Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexesJoshua E Allen, Roger Ferrini, David T Dicker, et al.
Pageof 10